Clinical trial · Observational
CADx - Radiomics to Distinguish the Origin of Ovarian Tumors
Computer-aided Radiology for Cancer Detection and Therapy Stratification - Benign or Malignant Ovarian Tumors.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In women with an ovarian tumor, it is often unclear whether the tumor is benign or malignant. To differentiate, tumor markers (CA125 and CEA), a transvaginal ultrasound and, depending on the ultrasound image and the CA125 concentration, a CT scan are performed. The quality of radiological imaging in diagnosing abdominal pathology is often not accurate enough, making additional interventions no-dig for proper classification and interpretation of the tumor. Objective: To improve accuracy for distinguishing benign from malignant disease in patients presenting with an ovarian mass by using a computer aided detection algorithm.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| CT-scan algorithm | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Sensitivity and specificity of CADx algorithm
- timeFrame
- 3 - 4 years
- description
- Percentage of correct determination of malignancy by the Risk of Malignancy Index (RMI) compared to exact determination by CAD assessment in patients with an ovarian tumor
Secondary outcomes (1)
- measure
- Sensitivity and specificity of CADx algorithm with additional variables
- timeFrame
- 3 - 4 years
- description
- Correlation of the findings from CAD analysis in some patients with analysis of circulating tumor (ct) DNA and protein tumor markers or other additional clinical variables
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients with an ovarian tumor of which it is unknown whether it is benign or malignant (Risk of Malignancy Index (RMI) \>200) * underwent surgery * histological proof of tumor Exclusion Criteria: * indefinite pathology report * lack of correct description of staging in OR report when applicable
References
Publications (0)
Data not yet available